Key statistics dashboard for Enliven Therapeutics, Inc. (ELVN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia.
Stock Data
| Price | $49.12 |
| Market Cap | $3.5B |
| Enterprise Value | $3.38B |
| Beta | 0.49 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -32.54 |
| Price / Book | 3.94 |
| P/S | 0.00 |
| EV/EBITDA | -31.90 |
| EV/Sales | 0.00 |
| EV/FCF | -50.35 |
| P/FCF | -56.86 |
| Earnings Yield | -3.26% |
| FCF Yield | -1.91% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -18.55% |
| Return on Assets | -11.64% |
| Return on Invested Capital | -13.88% |
| Return on Capital Employed | -13.88% |
Financial Health
| Current Ratio | 64.07 |
| Quick Ratio | 64.07 |
| Cash Ratio | 9.57 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.17% |
| Net Debt / EBITDA | 1.27 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 13.53 |
| Cash per share | 13.53 |
| FCF per share | -1.01 |
| Tangible Book Value per share | 13.53 |
| Dividend per share | 0.00 |
Related companies: ATAI · DNTH · IMTX · INBX · NKTR · ORIC · PGEN
Explore sector: Healthcare · Biotechnology
More sections of ELVN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks